Lynparza, Imfinzi combo recommended for nod in EU by CHMP for endometrial cancer: AstraZeneca Ruchika Sharma3 July 2024 10:00 AM ISTCambridge: AstraZeneca has announced that Imfinzi (durvalumab) and Lynparza (olaparib) have been recommended for approval in the European Union (EU)...
AstraZeneca Imfinzi fails in late-stage trial to treat type of lung cancer Ruchika Sharma30 Jun 2024 11:30 AM ISTCambridge: AstraZeneca has announced the high-level results from the ADJUVANT BR.31 Phase III trial, sponsored by the Canadian Cancer Trials...
AstraZeneca Imfinzi plus chemotherapy gets USFDA nod for mismatch repair deficient advanced or recurrent endometrial cancer Ruchika Sharma17 Jun 2024 11:30 AM ISTCambridge: AstraZeneca has announced that Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy has...
AstraZeneca Imfinzi plus chemotherapy approved in China for locally advanced or metastatic biliary tract cancer Ruchika Sharma19 Nov 2023 11:45 AM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
CDSCO nod to AstraZeneca cancer drug Tremelimumab Ruchika Sharma2 Jun 2023 11:53 AM ISTThe approval paves the way for the launch of Tremelimumab solution of 20 mg/ml (25 mg/1.25 ml and 300 mg/15 ml presentations in single-dose vials) in...
AstraZeneca announces positive results from ovarian cancer combo therapy trial Ruchika Sharma7 April 2023 11:30 AM ISTThe safety and tolerability of these combinations are broadly consistent with that observed in prior clinical trials and the known profiles of the...
Imfinzi plus Imjudo approved in EU for patients with advanced liver and non small cell lung cancers: AstraZeneca Ruchika Sharma25 Feb 2023 10:00 AM ISTUK: AstraZeneca has announced that Imfinzi (durvalumab) and Imjudo (tremelimumab) immunotherapy combinations have been approved in the European Union...
AstraZeneca gets Japanese approval for Imfinzi, Imjudo to treat 3 types of cancer Ruchika Sharma28 Dec 2022 11:30 AM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
Setback to AstraZeneca: Imfinzi fails as monotherapy for non-small lung cancer Ruchika Sharma20 Dec 2022 1:30 PM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
AstraZeneca Imfinzi plus chemotherapy recommended for marketing authorisation in EU for advanced biliary tract cancer Ruchika Sharma15 Nov 2022 5:44 PM ISTUK: AstraZeneca's Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult...
AstraZeneca tops quarterly estimates buoyed by cancer drug sales Ruchika Sharma13 Nov 2022 10:00 AM ISTDelaware: AstraZeneca on Thursday topped analysts' expectations for third-quarter profit and revenue, helped by sales of its key cancer drugs, and...
AstraZeneca gets USFDA nod for Imfinzi, Imjudo with chemotherapy to treat metastatic non-small cell lung cancer Ruchika Sharma11 Nov 2022 2:30 PM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
